Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Aptamer imaging with Cu-64 labeled AS1411: preliminary assessment in lung cancer.

Li J, Zheng H, Bates PJ, Malik T, Li XF, Trent JO, Ng CK.

Nucl Med Biol. 2014 Feb;41(2):179-85. doi: 10.1016/j.nucmedbio.2013.10.008. Epub 2013 Oct 29.

PMID:
24373858
2.

In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.

Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hoffman TJ.

J Nucl Med. 2007 Aug;48(8):1327-37. Epub 2007 Jul 13.

3.

Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.

Persson M, Hosseini M, Madsen J, Jørgensen TJ, Jensen KJ, Kjaer A, Ploug M.

Theranostics. 2013 Aug 3;3(9):618-32. doi: 10.7150/thno.6810. eCollection 2013.

4.

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.

Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, Waser B, Weber WA, Reubi JC, Maecke HR.

J Nucl Med. 2011 Jul;52(7):1110-8. doi: 10.2967/jnumed.111.087999. Epub 2011 Jun 16.

5.

Positron emission tomography based analysis of long-circulating cross-linked triblock polymeric micelles in a U87MG mouse xenograft model and comparison of DOTA and CB-TE2A as chelators of copper-64.

Jensen AI, Binderup T, Kumar EK P, Kjær A, Rasmussen PH, Andresen TL.

Biomacromolecules. 2014 May 12;15(5):1625-33. doi: 10.1021/bm401871w. Epub 2014 Apr 7.

PMID:
24645913
6.

Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.

Jiang M, Ferdani R, Shokeen M, Anderson CJ.

Nucl Med Biol. 2013 Feb;40(2):245-51. doi: 10.1016/j.nucmedbio.2012.10.010. Epub 2012 Dec 23.

7.

In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.

Kumar SR, Gallazzi FA, Ferdani R, Anderson CJ, Quinn TP, Deutscher SL.

Cancer Biother Radiopharm. 2010 Dec;25(6):693-703. doi: 10.1089/cbr.2010.0820.

8.

64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics.

Yang CT, Kim YS, Wang J, Wang L, Shi J, Li ZB, Chen X, Fan M, Li JJ, Liu S.

Bioconjug Chem. 2008 Oct;19(10):2008-22. doi: 10.1021/bc8002056. Epub 2008 Sep 3.

9.

(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.

Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, Anderson CJ.

Nucl Med Biol. 2009 Apr;36(3):277-85. doi: 10.1016/j.nucmedbio.2008.12.008.

10.

Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.

Hausner SH, Kukis DL, Gagnon MK, Stanecki CE, Ferdani R, Marshall JF, Anderson CJ, Sutcliffe JL.

Mol Imaging. 2009 Mar-Apr;8(2):111-21.

11.

Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.

Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ.

Clin Cancer Res. 2004 Dec 15;10(24):8674-82.

12.

Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.

Nguyen K, Parry JJ, Rogers BE, Anderson CJ.

Nucl Med Biol. 2012 Feb;39(2):187-97. doi: 10.1016/j.nucmedbio.2011.08.006. Epub 2011 Nov 4.

13.

Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.

Noaparast Z, Hosseinimehr SJ, Piramoon M, Abedi SM.

J Drug Target. 2015;23(6):497-505. doi: 10.3109/1061186X.2015.1009075. Epub 2015 Feb 12.

PMID:
25673264
14.

MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.

Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM.

Nucl Med Biol. 2015 Feb;42(2):71-7. doi: 10.1016/j.nucmedbio.2014.10.009. Epub 2014 Oct 22.

PMID:
25456837
15.

Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.

Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M.

J Nucl Med. 2011 Aug;52(8):1276-84. doi: 10.2967/jnumed.111.087700. Epub 2011 Jul 15. Erratum in: J Nucl Med. 2011 Sep;52(9):1498.

16.

Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.

Guo Y, Ferdani R, Anderson CJ.

Bioconjug Chem. 2012 Jul 18;23(7):1470-7. doi: 10.1021/bc300092n. Epub 2012 Jun 18.

17.

Development of [⁶⁴Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging.

Alirezapour B, Rasaee MJ, Jalilian AR, Rajabifar S, Mohammadnejad J, Paknejad M, Maadi E, Moradkhani S.

Nucl Med Biol. 2016 Jan;43(1):73-80. doi: 10.1016/j.nucmedbio.2015.07.012. Epub 2015 Aug 1.

PMID:
26453525
18.

Synthesis and comparative evaluation of novel (64)Cu-labeled high affinity cell-specific peptides for positron emission tomography imaging of tumor vasculature.

Merrill JR, Krajewski K, Yuan H, Frank JE, Lalush DS, Patterson C, Veleva AN.

Biomaterials. 2016 Apr;84:241-9. doi: 10.1016/j.biomaterials.2016.01.031. Epub 2016 Jan 21.

PMID:
26839954
19.

Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.

Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, Huston JS, Meares CF, Treves ST, Packard AB.

Nucl Med Biol. 2011 Jan;38(1):29-38. doi: 10.1016/j.nucmedbio.2010.07.003. Epub 2010 Oct 27.

20.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

Supplemental Content

Support Center